Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2019

Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2019

Summary

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) pipeline Target constitutes close to 25 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Tumor Necrosis Factor Receptor Superfamily Member 5 is a member of the TNF-receptor superfamily. This protein is a receptor on antigen-presenting cells of the immune system and is essential for mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. The interaction of this receptor and its ligand is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 7, 5, 6 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Report covers products from therapy areas Oncology, Immunology, Genito Urinary System And Sex Hormones, Central Nervous System, Dermatology, Gastrointestinal, Hormonal Disorders, Infectious Disease and Metabolic Disorders which include indications Non-Small Cell Lung Cancer, Solid Tumor, Melanoma, Pancreatic Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Kidney Transplant Rejection, Metastatic Melanoma, Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Kidney Cancer (Renal Cell Cancer), Lupus Nephritis, Lymphoma, Myasthenia Gravis, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Triple-Negative Breast Cancer (TNBC), Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Astrocytoma, Astrocytoma, Autoimmune Disorders, B-Cell Non-Hodgkin Lymphoma, Bile Duct Cancer (Cholangiocarcinoma), Central Nervous System (CNS) Tumor, Diffuse Large B-Cell Lymphoma, Focal Segmental Glomerulosclerosis (FSGS), Glioblastoma Multiforme (GBM), Glioma, Gliosarcoma, Graft Versus Host Disease (GVHD), Graves Diseases, Head And Neck Cancer, Heart Transplant Rejection, Hematological Tumor, Hepatic (Liver) Tumor, Hidradenitis Suppurativa, Hyperthyroidism, Leiomyosarcoma, Liposarcoma, Liver Transplant Rejection, Malignant Mesothelioma, Mantle Cell Lymphoma, Membranous Glomerulonephritis, Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Sclerosis, Non-Hodgkin Lymphoma, Pancreatic Islet Transplant Rejection, Pediatric Diffuse Intrinsic Pontine Glioma, Pemphigus, Prostate Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Sicca Syndrome (Sjogren), Soft Tissue Sarcoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Type 1 Diabetes (Juvenile Diabetes) and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope